These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36161830)

  • 41. Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial.
    Maturi RK; Glassman AR; Josic K; Antoszyk AN; Blodi BA; Jampol LM; Marcus DM; Martin DF; Melia M; Salehi-Had H; Stockdale CR; Punjabi OS; Sun JK;
    JAMA Ophthalmol; 2021 Jul; 139(7):701-712. PubMed ID: 33784735
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial.
    Brown DM; Ou WC; Wong TP; Kim RY; Croft DE; Wykoff CC;
    Ophthalmology; 2018 May; 125(5):683-690. PubMed ID: 29336896
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).
    Wykoff CC; Brown DM; Maldonado ME; Croft DE
    Br J Ophthalmol; 2014 Jul; 98(7):951-5. PubMed ID: 24518078
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multifocal electroretinography changes at the 1-year follow-up in a cohort of diabetic macular edema patients treated with ranibizumab.
    Baget-Bernaldiz M; Romero-Aroca P; Bautista-Perez A; Mercado J
    Doc Ophthalmol; 2017 Oct; 135(2):85-96. PubMed ID: 28779336
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anatomical and functional responses in eyes with diabetic macular edema treated with "1 + PRN" ranibizumab: one-year outcomes in population of mainland China.
    Lai K; Huang C; Li L; Gong Y; Xu F; Zhong X; Lu L; Jin C
    BMC Ophthalmol; 2020 Jun; 20(1):229. PubMed ID: 32539744
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Real-life experience of ranibizumab for diabetic macular edema in Taiwan.
    Tsai MJ; Hsieh YT; Peng YJ
    Int Ophthalmol; 2019 Jul; 39(7):1511-1522. PubMed ID: 29926364
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of baseline diabetic retinopathy status on initial anatomical response of intravitreal ranibizumab therapy for diabetic macular oedema.
    Nicholson L; Patrao NV; Ramu J; Vazquez-Alfageme C; Muwas M; Rajendram R; Hykin PG; Sivaprasad S
    Eye (Lond); 2017 Sep; 31(9):1358-1364. PubMed ID: 28452992
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials.
    Thach AB; Yau L; Hoang C; Tuomi L
    Ophthalmology; 2014 May; 121(5):1059-66. PubMed ID: 24424249
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema.
    Gerendas BS; Prager S; Deak G; Simader C; Lammer J; Waldstein SM; Guerin T; Kundi M; Schmidt-Erfurth UM
    Br J Ophthalmol; 2018 Feb; 102(2):195-203. PubMed ID: 28724636
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intravitreal aflibercept for diabetic macular oedema: Moorfields' real-world 12-month visual acuity and anatomical outcomes.
    Lukic M; Williams G; Shalchi Z; Sim D; Patel PJ; Keane PA; Hykin PG; Sivaprasad S; Menon D; Bruynseels A; Hamilton RD; Rajendram R
    Eur J Ophthalmol; 2020 May; 30(3):557-562. PubMed ID: 30808179
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Real-World Outcomes after 36-Month Treatment with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema (BOREAL-DME).
    Massin P; Creuzot-Garcher C; Kodjikian L; Girmens JF; Delcourt C; Fajnkuchen F; Glacet-Bernard A; Guillausseau PJ; Guthux F; Blin P; Grelaud A
    Ophthalmic Res; 2021; 64(4):577-586. PubMed ID: 32932257
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema.
    Wong Y; Steel DHW; Habib MS; Stubbing-Moore A; Bajwa D; Avery PJ;
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):733-742. PubMed ID: 27957600
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and Safety of Ranibizumab in Asian Patients with Branch Retinal Vein Occlusion: Results from the Randomized BLOSSOM Study.
    Wei W; Weisberger A; Zhu L; Cheng Y; Liu C;
    Ophthalmol Retina; 2020 Jan; 4(1):57-66. PubMed ID: 31902472
    [TBL] [Abstract][Full Text] [Related]  

  • 54. One-year real-life results on effect of intravitreal aflibercept in patients with diabetic macular oedema switched from ranibizumab.
    Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R
    Eur J Ophthalmol; 2021 May; 31(3):1171-1176. PubMed ID: 32452251
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data.
    Sadda SR; Campbell J; Dugel PU; Holekamp NM; Kiss S; Loewenstein A; Augustin AJ; Shih V; Xu X; Wykoff CC; Whitcup SM
    Eye (Lond); 2020 Mar; 34(3):480-490. PubMed ID: 31320738
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized Trial of Monthly Versus As-Needed Intravitreal Ranibizumab for Radiation Retinopathy-Related Macular Edema: 1-Year Outcomes.
    Schefler AC; Fuller D; Anand R; Fuller T; Moore C; Munoz J; Kim RS;
    Am J Ophthalmol; 2020 Aug; 216():165-173. PubMed ID: 32278771
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results.
    Payne JF; Wykoff CC; Clark WL; Bruce BB; Boyer DS; Brown DM;
    Br J Ophthalmol; 2021 Feb; 105(2):253-257. PubMed ID: 32303499
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab.
    Sophie R; Lu N; Campochiaro PA
    Ophthalmology; 2015 Jul; 122(7):1395-401. PubMed ID: 25870079
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study.
    Lang GE; Berta A; Eldem BM; Simader C; Sharp D; Holz FG; Sutter F; Gerstner O; Mitchell P;
    Ophthalmology; 2013 Oct; 120(10):2004-12. PubMed ID: 23725735
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.
    Wykoff CC; Chakravarthy U; Campochiaro PA; Bailey C; Green K; Cunha-Vaz J
    Ophthalmology; 2017 Apr; 124(4):440-449. PubMed ID: 28081945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.